Rhythm Pharmaceuticals Inc.

Rhythm Chair, President and Chief Executive Officer David Meeker, M.D., will discuss Rhythm’s efforts to transform the care of patients with rare neuroendocrine diseases during a fireside chat at Bank of America’s 24th Annual Employee Healthcare Conference on Tuesday, May 14, 2024, at 5:20 ET in Las Vegas, NV. Details: https://lnkd.in/eM9JU8WU

The European Association for the Study of Obesity (EASO)'s 31st European Congress on Obesity is underway in Venice! Rhythm will be showcasing five graphical abstracts and one oral presentation related to our research in #hyperphagia and severe #obesity due to rare MC4R pathway diseases. In addition, at 1:45PM CEST on Tuesday, May 14, Rhythm will sponsor a satellite symposium titled “Precision medicine in treating leptin melanocortin-4 receptor (MC4R) pathway diseases: Addressing hyperphagia and early-onset, severe obesity.” #ECO2024

Rhythm is excited to attend the European Association for the Study of Obesity (EASO)’s 31st European Congress on Obesity from May 12-15 in Venice. We look forward to engaging with physicians and other healthcare professionals to discuss and learn more about the latest topics in #obesity medicine. #ECO2024

We are looking forward to another day at the European Society of Endocrinology's European Congress of Endocrinology in Stockholm! Tomorrow, Monday, May 13 at 9:45AM CET, Rhythm is sponsoring a Hub Session intended for HCPs only titled, “The role of precision medicine in managing rare MC4R pathway disease, from monogenic obesity to Bardet-Biedl syndrome.” #ECE2024

The European Society of Endocrinology’s European Congress of Endocrinology is underway in Stockholm! Rhythm is sponsoring a Hub Session on Sunday, May 12 at 4:25PM CET titled, “Rare hypothalamic melanocortin-4 receptor (MC4R) pathway diseases: hyperphagia and early-onset, severe obesity.” Rhythm also had five e-posters accepted that showcase our research related to #hyperphagia and severe #obesity due to rare MC4R pathway diseases. #ECE2024

We are excited to attend the European Society of Endocrinology’s European Congress of Endocrinology May 11-14 in Stockholm! The Rhythm team is looking forward to connecting with industry peers and endocrinology leaders. #ECE2024

Earlier this week Rhythm hosted a conference call discussing first quarter 2024 financial results. Read more here: https://lnkd.in/eTvdZ4pW

#ICYMI We recently announced the publication of results from our investigational Phase 2 study in #hypothalamic #obesity in the peer-reviewed journal The Lancet Diabetes & Endocrinology. Read our press release to learn more: https://lnkd.in/ex5vVVYf

Thank you to the Pediatric Endocrine Society for hosting a successful #PES2024! We enjoyed sharing our latest updates in the MC4R pathway disease space and engaging with other researchers and clinicians to learn about the latest advances in pediatric endocrinology.

Rhythm management discussed 1Q 2024 commercial sales and the latest on our progress in Europe, clinical trial milestones and more. You can watch the recording here: https://lnkd.in/eWMj9wQZ